EMEA-001864-PIP01-15-M07
Key facts
| Invented name |
Takhzyro
|
| Active substance |
Lanadelumab (DX-2930)
|
| Therapeutic area |
Other
|
| Decision number |
P/0214/2022
|
| PIP number |
EMEA-001864-PIP01-15-M07
|
| Pharmaceutical form(s) |
Solution for injection
|
| Condition(s) / indication(s) |
Prevention of hereditary angioedema attacks
|
| Route(s) of administration |
Subcutaneous use
|
| Contact for public enquiries |
Takeda Pharmaceuticals International AG Ireland Branch
E-mail: medinfoemea@takeda.com |
| Decision type |
PM: decision on the application for modification of an agreed PIP
|
| Compliance procedure number |
EMEA-C-001864-PIP01-15-M07
|
| Compliance opinion date |
09/09/2022
|
| Compliance outcome |
positive
|